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ABSTRACT
We have previously characterized that FasL and Apo2L/TRAIL are stored in 
their bioactive form inside human T cell blasts in intraluminal vesicles present in 
multivesicular bodies. These vesicles are rapidly released to the supernatant in the 
form of exosomes upon re-activation of T cells. In this study we have compared for the 
first time proteomics of exosomes produced by normal human T cell blasts with those 
produced by tumoral Jurkat cells, with the objective of identify proteins associated with 
tumoral exosomes that could have a previously unrecognized role in malignancy. We 
have identified 359 and 418 proteins in exosomes from T cell blasts and Jurkat cells, 
respectively. Interestingly, only 145 (around a 40%) are common. The major proteins in 
both cases are actin and tubulin isoforms and the common interaction nodes correspond 
to these cytoskeleton and related proteins, as well as to ribosomal and mRNA granule 
proteins. We detected 14 membrane proteins that were especially enriched in exosomes 
from Jurkat cells as compared with T cell blasts. The most abundant of these proteins 
was valosin-containing protein (VCP), a membrane ATPase involved in ER homeostasis 
and ubiquitination. In this work, we also show that leukemic cells are more sensitive 
to cell death induced by the VCP inhibitor DBeQ than normal T cells. Furthermore, VCP 
inhibition prevents functional exosome secretion only in Jurkat cells, but not in T cell 
blasts. These results suggest VCP targeting as a new selective pathway to exploit in 
cancer treatment to prevent tumoral exosome secretion.
INTRODUCTION
Multivesicular bodies are compartments inside 
cells different for endosomes and lysosomes. In these 
compartments there are intralumenal vesicles, which 
once secreted to the extracellular medium, are termed 
exosomes. These exosomes have a particular lipid and 
protein composition, and a size between 40 to 100 nm. 
These structures were described for the first time during 
maturation of erythrocytes [1–4]. In 1975 these structures 
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were isolated in calf fetal serum [5]. Thereafter, exosomes 
have been described to be released in physiological 
conditions by different cell types like melanocytes [6], T 
lymphocytes [7, 8], B lymphocytes [9], dendritic cells [10, 
11], platelets [12], mast cells [13], trophoblasts [14], and 
intestinal, prostate and intraocular epithelial cells [15–17]. It 
has been also described that exosomes are present in colon 
mucosa [18], in lactating mammary glands [19], human 
urine [20] and human bronco alveolar fluid [21]. More 
recent reviews summarize all the biological fluids and cell 
types where exosomes have been described [22–24].
Our group characterized previously that FasL and 
Apo2L/TRAIL are stored inside human T cell blasts in 
multivesicular bodies [25], and that they were rapidly 
released to the supernatant in their bioactive form 
associated with exosomes upon re-activation [8, 25], a 
paradigm that has been confirmed by other groups [24, 
26, 27]. This membrane-bound secretion of death ligands 
allowed these molecules to conserve their pro-apoptotic 
potential, and participate in the down-modulation of 
T cell-mediated immune responses. The physiological 
importance of this mechanism has been demonstrated in 
mice knockout for the Wiskott-Aldrich syndrome (WAS) 
protein. WAS deficiency is primarily characterized as an 
immunodeficiency, that progresses to autoimmunity. In 
these mice, autoimmunity manifestations are associated 
with the inability of T cells to secrete functional FasL 
associated with exosomes [28]. Furthermore, our 
group characterized a similar situation in CTL clones 
from Chediak-Higashi patients. These patients suffer 
also from autoimmunity associated with problems in 
granule secretion [29]. In addition, a low amount of 
FasL and/or Apo2L/TRAIL-carrying exosomes has been 
detected in synovial fluids from rheumatoid arthritis 
patients [30]. This observation led to the generation of 
liposomes decorated with Apo2L/TRAIL and their use 
as a successful treatment in a rabbit model of rheumatoid 
arthritis [31]. Recently, a similar immunoregulatory role 
has been described for exosomes produced by activated 
humans NK cells [32]. Moreover, FasL secretion on the 
surface of exosomes has been also described in the case of 
trophoblasts, where it accomplish an important function in 
the attenuation of the immune response against the fetus, 
preventing spontaneous abortion [14, 33].
On the other hand, exosome secretion has been also 
described in different types of tumoral cells [34–36]; see also 
the Exocarta and Vesiclepedia websites http://exocarta.org/
index.html; http://www.microvesicles.org). In some cases, 
the secretion of exosome-associated FasL by tumoral cells 
has been correlated with tumor counterattack mechanisms to 
escape immunosurveillance by T cells [35, 37–42].
Proteomic analysis of exosomes has been done 
in B cells [43], dendritic cells [44], intestinal epithelial 
cells [15], in exosomes isolated from malignant pleural 
effusion [45], human urine [20] and many other cell types 
and biological fluids, a compendium of which is available 
at the recent Exocarta and Vesiclepedia websites [46, 47]. 
More recently, the presence of microRNA in exosomes 
has drawn attention on this new system of cell to cell 
communication and regulation of gene expression ([48, 
49], see also [50] for a recent review, and the adapted 
Exocarta and Vesiclepedia websites).
In spite of all the extensive and expanding work 
performed on exosome characterization, few systematic 
studies are available comparing proteomics of exosomes 
produced by tumoral cells with their healthy cell 
counterpart. Taking into account that exosome secretion 
is a recognized mechanism of cell-to-cell communication, 
it would be of interest to make this comparison in order to 
identify proteins that could perform a pro-transformation 
task, or, on the contrary, regulatory proteins that are 
associated with exosomes from healthy cells that are lost 
in exosomes from tumoral cells.
In this work, we performed a proteomic analysis 
of exosomes present in human T cell blasts, and we 
compared with those of the tumoral cell line Jurkat. Our 
analysis revealed differential protein expression between 
both types of exosomes. We further characterized the 
selective enrichment of VCP only in exosomes of 
tumoral origin. Of interest, Jurkat tumoral cells are more 
sensitive to cell death induced by the VCP inhibitor 
DBeQ than normal T cells. Furthermore, VCP inhibition 
preventsfunctionalexosome secretion only in Jurkat cells, 
but not in T cell blasts. These results suggest targeting of 
VCP as a new candidate for anti-tumoral agents.
RESULTS
Exosome detection by electron microscopy
Previous studies of our group demonstrated by 
immunoblot and functional assays the secretion of 
FasL and Apo2L/TRAIL associated with a particulate, 
ultracentrifugable fraction, during activation-induced 
cell death of human T cell blasts and tumoral Jurkat 
cells. We have also showed by immunofluorescence and 
immunoelectron microscopy (IEM) that FasL and Apo2L/
TRAIL were stored inside cytoplasmic multivesicular 
bodies, associated preferentially with intraluminal vesicle 
membranes [8, 25]. In this work, for the first time, we 
show an IEM view of isolated exosomes secreted from 
T cell blasts pulsed 5 minutes with PHA (Figure 1A) or 
stimulated during 3h with immobilized anti-CD59 mAb 
(Figure 1B). Exosomes secreted from PHA-stimulated T 
cell blasts contained both FasL (15 nm dots), and Apo2L/
TRAIL (5 nm dots, marked with arrowheads; Figure 
1A ). However, in exosomes secreted from anti-CD59 
mAb-stimulated T cell blasts, only Apo2L/TRAIL can 
be detected (Figure 1B). The size of the exosomes are 
between 100 and 130 nm, in agreement with the unlabeled 
structures detected previously by scanning electron 
microscopy [8].
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Lipid composition of exosomes secreted by 
Jurkat cells or human T-cell blasts
Lipid composition of Jurkat cells and of exosomes 
was analyzed as indicated in Materials and Methods. First, 
we separated the different phospholipid classes from neutral 
lipids. The main difference between exosome and cell lipids 
was the enrichment in sphingomyelin (SM) in exosome 
lipids. We also observed partial reductions in the PI+PS 
percentage and also in that of neutral lipids, being PC the 
major lipid in both cases (Figure 2). Afterwards, we separated 
neutral lipids classes. The main difference in this fraction 
was the enrichment in cholesterol, with a concomitant 
reduction in the free fatty acid amount (Figure 2). These 
differences between exosome and cellular lipids were also 
observed in the T cell blast model (data not shown). This lipid 
composition makes exosomes more rigid structures than cell 
membranes, and defines them as non-fusogenic vesicles. 
These results are mostly in agreement with previous lipid 
analysis of exosomes produced from B cells [43].
Immunoblot detection of specific proteins 
associated with jurkat and T-cell blasts exosomes
Before beginning the proteomic analysis of 
exosomes, we decided to characterize the purity of isolated 
exosomes by immunoblot. One one hand, we were able to 
detect the expression of the cytosolic chaperones Hsp90 and 
Hsp70 in exosomes from Jurkat cells. Hsp70 expression 
was detected by MALDI-TOF analysis in exosomes of 
dendritic cells [44]. On the other hand, the mitochondrial 
chaperone Hsp60 and the chaperone Hsp40 were not 
detected in those exosomes, confirming the specificity in 
the exosome isolation process (Figure 3A). Furthermore, we 
detected the presence of the death ligands Apo2L/TRAIL 
and FasL in these isolated exosomes, confirming previous 
data ([8, 25] and Figure 1). FasL is synthesized as a 32 
kDa polypeptide that is glycosylated during their synthesis. 
Partial glycosylation generates a doublet at around 37 
kDa and full glycosylation generates a mature form of 
41 kDa. While all the isoforms are equally represented in 
cell extracts, exosomes contained predominantly the non-
glycosylated polypeptide (Figure 3A).
As previously reported for exosomes of human 
T cell origin[51], we also detected the protein tyrosine 
kinase p56lck. The microtubule and cytoskeleton proteins 
α-tubulin and β-actin were also detected in these 
exosomes, as previously described on exosomes from 
different cell types. Finally, the vesicular transport protein 
Rab5 was not detected, indicating again the specificity of 
protein distribution in the isolated exosomes (Figure 3A).
The exosomes from T cell blasts share protein 
expression with those from Jurkat cells, compare the 
corresponding lanes in Figure 3B. Both types of exosomes 
contain the chaperones Hsp90, Hsp70 and TCP-1α, the 
tetraspanin CD63, and also α-tubulin and β-actin. In addition, 
we showed the absence of the ER soluble marker Grp94 in 
exosomes from both Jurkat cells and T cell blasts, as an 
additional control of specific protein distribution in exosomes 
(Figure 3B).
Figure 1: Localization of FasL and Apo2L/TRAIL in exosomes derived from human T cell blasts. Human T cell blasts were 
stimulated with PHA for 5 minutes, PHA washed out, and supernatants collected 1 hour later A. or they were stimulated with immobilized 
anti-CD59 mAb VJ1/12.2 for 3h and supernatants collected B.. Exosomes present in supernatants were placed on bacitracin-treated grids 
as indicated in Material and Methods and observed by TEM. In both cases, FasL (15 nm dots) and APO2L/TRAIL (5 nm dots, marked 
with arrows in A) were located using, respectively, N20 rabbit pAb and 5C2 mouse mAb, plus secondary anti-rabbit and anti-mouse IgGs.
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2D separation of cell and exosome proteins and 
MALDI-TOF identification of exosomal proteins
As a first approach to the proteomic charact-
erization of exosomes from Jurkat and T cell blasts, we 
performed 2D electrophoresis separation of proteins 
obtained from cells or from exosomes. As shown in 
Supplementary Fig 1, the proteome of Jurkat cells is 
much more complex than that of their derived exosomes 
or of the exosomes derived from T cell blasts. The 
next step was the characterization by MALDI-TOF of 
proteins obtained from the 2D gels. The identification 
of several of the major proteins by this technique is 
indicated in Figure 4, on a 2D gel corresponding to 
proteins from Jurkat exosomes. The samples marked 
from 1 to 3 correspond to actin isoforms, and those 
marked from 4 to 7 correspond to tubulin isoforms. 
Those are major structural proteins of the cells, 
which have been identified in exosomes from all cell 
types studied to date. In addition, we detected 4 
major proteins:
-  vimentin (sample 8), protein included in the 
intermediate filaments of class III and implicated 
in vesicular traffic.
-  major vault protein (MVP; sample 9), protein of 
unknown function, that is indirectly related with 
vesicular transport between the nucleus and the 
cytoplasm
-  p85Mcm or minichromosome maintenance protein 
7 (MCM7; sample 10), nuclear protein implicated 
in cell cycle control and proliferation, not 
previously described in association with exosomes
-  heterogeneous nuclear riboprotein A2/B1 
(HNRPA2B1; sample 11), a protein quantitatively 
important in the composition of these exosomes. 
This protein has been recently shown to be 
involved in the enrichment of specific miRNAs 
in exosomes[52].
Figure 2: Lipid composition of Jurkat cells and of derived exosomes. Cells were first metabolically labeled with [14C]-acetate 
during 72h. Then, cells were stimulated with PHA as indicated in the legend of Figure 1, cells separated from supernatants by centrifugation, 
and exosomes isolated from the supernatants as indicated in Materials and Methods. Cell or exosome lipids were extracted and subjected 
to thin-layer chromatography, and radiolabelled bands revealed by autoradiography. Bands were marked in the thin layers, scraped, and 
radioactivity determined in a b-counter by liquid scintillation. Results are shown as percentage of the total labeling (left graphic) or of 
the labeling corresponding to neutral lipids (right graphic). PI, phosphatidylinositol; PS, phosphatidylserine; SM, sphingomyelin; PC, 
phosphatidylcholine; PE, phosphatidylethanolamine; CL, cardiolipin; NL, neutral lipids; TAG, triacylglycerol; FFA, free fatty acids; Chol, 
cholesterol; DAG, diacylglycerols; MAG, monoacylglycerol. The results are expressed as the mean±SD of two different analysis. *, P<0.05.
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Figure 3: Initial immunoblot analysis of proteins expressed in cells and in exosomes. Protein extracts were obtained from 
cells or from exosomes, proteins separated by electrophoresis in Nu-PAGE Bis-Tris 12% gels, proteins transferred to PVDF membranes and 
proteins revealed by immunoblot using specific antibodies. In all cases, extracts correspond to 5 μg of total protein. A. proteins from whole 
Jurkat cell extracts (1) or from exosomes secreted by Jurkat cells after pulse-stimulation with PHA (2). B. proteins from whole Jurkat cell 
extracts (1), from exosomes secreted by Jurkat cells after pulse-stimulation with PHA (2) or from exosomes secreted by human T cell blasts 
pulse-stimulated with PHA (3). In the case of CD63, proteins from non-stimulated Jurkat cells (1), from Jurkat cells pulse-stimulated with 
PHA (2), from exosomes secreted by Jurkat cells after pulse-stimulation with PHA (3) or from exosomes secreted by human T cell blasts 
pulse-stimulated with PHA (4). Molecular weights are indicted on the left.
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All these proteins were identified in similar analysis 
made on exosomes from T cell blasts, except p85Mcm/
MCM7, that was not detected, indicating an exclusive 
association with tumoral exosomes.
Additional analysis performed revealed 30 additional 
proteins in exosomes from Jurkat cells or T cell blasts, finding 
some interesting specificities in their distribution. Hence, 17 
proteins were detected in exosomes from both cell types: 
annexin-I and VI, Na+/K+ ATPase, GAPDH, nucleolin, 
tropomyosin-3, 3 histones and 8 ribosomal proteins; 3 
proteins were identified only in exosomes from Jurkat cells; 
CD3-ζ, signal recognition protein (SRP) and Y-box binding 
protein-1 (YBX-1); and 10 proteins were only detected in 
exosomes from normal T cell blasts: CD3-d, β2 integrin, 
ADP ribosylation factor-6 interacting protein, HLA-I, β2-
microglobulin, CD97, CD5, CD48, interferon-induced 
transmembrane protein-1 (IFITM-1) and Arp2/3.
All these proteins have been identified previously 
in proteomic analysis of exosomes, although not all of 
them in exosomes from T cells or leukemic cells (see 
the Exocarta webpage). It is interesting to note that with 
a reduced number of proteins identified, a number of 
specific locations in exosomes from tumoral or normal T 
cells, have been already found.
Figure 4: 2D separation of proteins in Jurkat exosomes. A 2D gel was performed on a sample of 30 μg total protein extracted 
from Jurkat exosomes and protein spots silver-stained. Isoelectric point is indicated above and molecular weight on the left. The image is 
representative of at least 5 different gels performed. Numbered spots were identified by MALDI-TOF, see text of Results for details.
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Proteomic analysis of exosomal proteins by 
LCMSMS
The LCMSMS technique is a technique much 
more sensitive than 2D separation of proteins followed 
by MALDI-TOF identification. For example, in the most 
complete proteomic study performed to date on T cell 
exosomes, made in murine T cells, 690 proteins have 
been identified using this technique [52], while we had 
identified only 43.
Hence, we have performed a complete LCMSMS 
study, using exosomes from Jurkat cells or from normal 
T cells blasts, wit the necessary repetitions. We have 
identified 359 proteins in exosomes from T cell blasts 
and 418 in exosomes from Jurkat cells, of which only 145 
(around a 40%) are common (Figure 5A). The complete 
list of all proteins identified, separating those that are 
shared, and those expressed exclusively in exosomes from 
Jurkat tumoral cells or from normal human T cell blasts, is 
shown in Supplementary Table 1.
The clustering of these proteins by their interaction 
profiles using the STRING software shows two defined 
and major interaction nodes in both T cell blasts and Jurkat 
T cells. This two major clusters corresponded to ribosomal 
proteins (cluster at the top left) and to mRNA granule 
proteins (cluster at the top right; Figure 5B ). There is 
another common cluster of interaction, corresponding to 
proteins implicated in vesicular traffic. In the case of T 
cell blasts, there is another cluster of interaction, which 
is absent in exosomes from Jurkat cells. This cluster 
corresponds to membrane T cell proteins that stimulate 
or suppress T cell function, such as Fas/CD95, CD44, 
CD97, CD5, CD38, CD46, and other interacting proteins. 
In Jurkat cells, another interacting cluster appears between 
the two upper ones, corresponding to actin, tubulin, 
and cytoskeletal and microtubule interacting proteins. 
Although this cluster is not clearly detected in exosomes 
from T cell blasts, these proteins are the major ones in 
these exosomes, so it is not a cluster exclusive of tumoral 
Jurkat cells.
Membrane proteins preferentially enriched in 
Jurkat and T-cell blasts exosomes
It is tempting to speculate that mostly membrane 
proteins could have a specific function in exosomes, since 
most of the proteins found inside exosomes are rather 
cytoplasmic proteins localized there due to the mechanism 
of exosome generation by inward vesiculation of the external 
MVB membrane. Hence, we have separated the membrane 
proteins that are detected by proteomic techniques only in 
exosomes from Jurkat cells or from T cell blasts. We show 
in Table 1 that, while in T cell blast exosomes predominate 
normal “cluster of differentiation “ (CD) immune membrane 
proteins, with their known regulatory functions, those were 
mostly absent from Jurkat exosomes. These proteins are 
coincident with those present in the cluster or interaction 
that we showed specific for T cell blasts in Figure 5B . In 
addition, components of the antigen presentation machinery, 
including several HLA proteins, β2-microglobulin and the 
invariant chain (CD74) are detected exclusively in the 
membrane of T cell blast exosomes. On the contrary, 14 
membrane proteins are detected only in exosomes from 
Jurkat cells and could have a previously non-described role 
in malignancy (Table 1). Most of these proteins (VAMPs, 
VAMP-associated proteins, dynein, syntaxin 12, lamp1) are 
related with vesicular traffic processes. However, the most 
abundant of these proteins was VCP.
VCP experiments
p97/VCP is a membrane ATPase involved in ER 
homeostasis and ubiquitination [53]. It has been associated 
with tumoral transformation, having prognostic value, at 
least in gastric carcinoma [54]. First of all, we confirmed 
this specific distribution of VCP in Jurkat exosomes by 
immunoblot. As shown in Figure 6, VCP is an abundant 
protein both in T cell blasts and in Jurkat cells at the basal 
stage. The protein is not detected in exosomes from T cell 
blasts culture supernatants, but it could be already detected 
in exosomes from Jurkat cell supernatants at the basal stage. 
When T cell blasts or Jurkat cells were pre-stimulated with 
PHA for 5 min, PHA washed, cells resuspended in fresh 
medium, and supernatants collected 1h later, as described 
above in our exosome proteomic analysis, VCP release 
associated with exosomes was much higher in the case 
of Jurkat cells than in the case of T cell blasts. In fact, the 
amount of VCP secreted from Jurkat cells in 1h, expressed 
as the ratio with cellular β-actin, is higher that the amount 
still present inside the cells. In the case of normal T cell 
blasts, although a small amount of VCP could be detected 
in the supernatant after 1h, most VCP is still present inside 
the cells (Figure 6B). In fact, VCP was enriched in Jurkat 
exosomes at an 8-fold higher rate than in T cell blasts 
exosomes after activation, as shown in the lower panel 
of Figure 6B.
We further tested whether the enrichment of VCP 
in exosomes from tumoral cells have a physiological role. 
To that end, we used a recently developed reversible VCP 
inhibitor, termed DBeQ. This diamine was characterized 
by high-throughput screening between more than 200,000 
compounds as the most potent and specific for p97/VCP 
inhibition [62]. As shown in Figure 7A , DBeQ was toxic 
for tumoral Jurkat cells, but not for freshly isolated PBMC 
or derived T cell blasts at doses up to 6 μM. This result 
indicates that VCP activity is needed for tumoral cell 
survival, while normal human T cells are not so dependent 
on this ATPase for survival. We extended these results 
obtained in Jurkat cells to other human leukemias, such 
as the promonocytic leukemia U937 and the chronic 
lymphocytic leukemia B cell line Mec1, which showed 
similar IC50 as the acute T cell leukemia Jurkat (Figure 7B).
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Figure 5: Exosomal proteins detected by LCMSMS. 4 different samples obtained from Jurkat cells and samples obtained from 4 
different donors were analyzed by LCMSMS. Upper panel, the number of proteins with an statistically significant identification identified 
in exosomes from Jurkat cells or from human T cell blasts, indicating the number of proteins that were common are represented in a Venn 
diagram; Lower panels, protein interaction networks obtained using the STRING software between proteins identified in human T cell blast 
exosomes (middle panel) or in Jurkat cells (lower panel).
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To investigate the effect of DBeQ on exosome 
release, we used a bioassay previously optimized by 
our group [55, 56]. Briefly, supernatants of T cell blasts 
or Jurkat cells stimulated with PMA plus ionomycin 
are tested against non-stimulated Jurkat cells. In our 
previous studies, we have shown that cytotoxicity 
on Jurkat cells of these supernatants is mainly due to 
FasL and Apo2L/TRAIL secretion associated with 
exosomes [8, 56, 57], being thus a functional test of 
exosome secretion. Before performing the bioassays 
to test exosome secretion in the presence of DBeQ, 
we demonstrated that DBeQ does not inhibit anti-Fas 
mAb or recombinant TRAIL-induced apoptosis on 
Jurkat cells, while the general caspase inhibitor Z-VAD-
fmk does inhibit death receptor-induced apoptosis, as 
previously reported (Figure 8A). The absence of DBeQ 
effect on Fas- or TRAIL receptor-induced apoptosis 
was observed either if 3 μM of the VCP inhibitor was 
present during the overnight assay or if cells were pre-
incubated during 16h with DBeQ and then washed out 
before the assay. As an additional control, we show that 
incubation during 16h with this concentration of DBeQ 
does not decrease FasL or TRAIL expression in Jurkat 
cells (Figure 8B). As shown in Figure 8C , supernatants 
from non-stimulated T cell blasts, pre-incubated with 
or without DBeQ, are not cytotoxic against Jurkat 
cells. In addition, supernatants from re-activated T 
cell blasts in the presence or absence of DBeQ were 
equally cytotoxic against Jurkat cells. In the case of 
supernatants from non-stimulated Jurkat cells, we could 
Table 1: Membrane proteins differentially detected by MS-based methods in exosomes from T cell blasts or Jurkat 
cells
Only in T cell blasts exosomes (25) Only in Jurkat cell exosomes (14)
Syntaxin 7 CD3ζ*
Syntaxin 4 Myobrevin (VAMP5)
Integrin β2 Cellubrevin (VAMP3)
HLA-I-B & C VAMP-associated protein B (VAPB)
2-microglobulin VAMP-associated protein A (VAPA)
CD74 (invariant chain) ICAM2
CD3δ ATP6V1EI
CD5 Dynein
CD46 Lamin B receptor
CD2 Ryanodine receptor
CD63** Syntaxin 12
CD48 Lamp1
CD58 VCP
CD44 KDEL retention receptor 2
CD38
CD6
CD97
IFITM1
IFITM3
Fas (CD95)
ICAM3
LAIR1
SLAMF6
LFA-1
*(only detected by MALDI-TOF)
**(detected by immunoblot in Jurkat cell exosomes)
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detect some cytotoxicity, that is increased after PMA 
+ ionomycin stimulation. In both cases, preincubation 
with DBeQ inhibited significantly the secretion of 
cytotoxic exosomes from Jurkat cells (Figure 8D). Our 
results indicate that VCP is needed for the secretion 
of exosomes from tumoral Jurkat cells, but not from 
normal human T cell blasts. These results also point to 
a higher basal level of functional exosome generation 
in the case of tumoral Jurkat cells than in the case of 
normal human T cell blasts.
Figure 6: Analysis of VCP expression in cells and exosomes. A. Levels of VCP protein both in cell extracts and in exosomes 
were analyzed by Wetern blot. Both T cell blastas and Jurkat cells were unstimulated or stimulated with PHA for 5 min. Then, PHA was 
removed and cells were suspenden in fresh medium. Finally, supernatants were collected 1h later and proteins extracted. Cell and exosome 
proteins were separated by electrophoresis and VCP immunoblotted with an specific antibody. The levels of β-actin were also determined 
in the same gels as a control of protein loading. B. Upper graphs show the relative intensity of the VCP bands as a ratio with cellular β-actin 
expression, analyzed using the ImageJ software. Lower graph shows the VCP enrichment in exosomes, expressed as the ratio between 
exosome and celular VCP in each experimental condition. The results are expressed as the mean±SD of two different experiments.
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Figure 7: Effect of the VCP inhibitor DBeQ on leukemic and normal lymphocytes. Dose-response assays using the indicated 
doses of DBeQ were performed on freshly isolated PBMC, derived T cell blasts and Jurkat cells A., or on leukemic U937, Mec1 and Jurkat 
cells B.. The decrease in cell viability was measured using the MTT assay after 24h of incubation. The results are expresses as the mean±SD 
of at least two different experiments. **, P < 0.01.
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Figure 8: Effect of the VCP inhibitor DBeQ on exosomes release from T cell blasts or from tumoral Jurkat cells. 
A. Jurkat cells were either left untreated (control) or they were treated overnight with 1 μg/ml of soluble TRAIL or with 50 ng/ml of the 
anti-Fas mAb CH11, in the presence or absence of 30 μM of the caspase inhibitor Z-VAD-fmk, as indicated (white bars). The possible 
effect of DBeQ was tested using two incubation protocols. In the first one (black bars), 3 μM DBeQ was present during the overnight 
assay, and in the second (grey bars), cells were pre-incubated with 3 μM for 16h before the incubation with anti-Fas of with TRAIL and the 
assay performed in the absence of DBeQ. Cell death was determined by flow cytometry using 7-amino-actinomycin D (7-AAD) staining. 
The results are expressed as the mean±SD of at least two different experiments. B. Jurkat cells were incubated in the presence or absence, 
as indicated, of 3 μM DBeQ for 16h, cell extracts were obtained, and the expression of TRAIL or FasL was determined by immunoblot. 
C, D. T cell blasts and Jurkat cells were cultured in the presence or in the absence of 3 μM DBeQ for 16h. Then, DBeQ was removed and 
cells were stimulated with 10 ng/ml phorbol myristate-acetate (PMA) plus 600 nM ionomycin during 2h. After that, cell supernatants were 
collected by centrifugation, and their cytotoxicity was tested overnight against non-activated Jurkat cells. Finally, cell death was determined 
by flow cytometry using 7-amino-actinomycin D (7-AAD) staining. The results are expressed as the mean±SD of at least two different 
experiments. **, P < 0.01. C. Cytotoxic effect of supernatants from T cell blasts. D. Cytotoxic effect of supernatants from Jurkat cells.
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DISCUSSION
To our knowledge, this is the first systematic and 
proteomic study of exosomes secreted by human leukemic 
cells and their healthy counterparts.
In the present study we have confirmed our previous 
data on FasL and Apo2L/TRAIL functional secretion 
in association with exosomes [8, 25], by additionally 
showing the presence of FasL and/or Apo2L/TRAIL 
in isolated exosomes by IEM and by immunoblot. This 
has been recognized as a mechanism of immune down-
modulation [27, 28], also in the prevention of abortions 
[58], and the release of FasL-carrying exosomes by tumor 
cells recognized as a mechanism of tumor counter-attack 
against immune surveillance [39–41]. However, it is 
remarkable that neither FasL nor Apo2L/TRAIL have 
been detected by proteomic analysis using MS-detection 
based methods. This could be due to the glycosylation 
nature of these membrane proteins, which could decrease 
their solubilization and/or to their trypsin processing. It is 
remarkable that in a thorough proteomic study in which 
two different intracellular granule populations are detected 
in activated human T cells, characterized by the presence 
of FasL in one of them and of granzyme B in the other 
population, FasL was also not detected by ME-based 
proteomics even in the granules that were characterized 
by their presence [59]. Also, perforin and granzyme B 
have not been detected in exosomes, but granzyme A has 
been detected exclusively in exosomes from human T cell 
blasts, but not in exosomes from Jurkat cells, as expected 
from the presence of cytotoxic CD8+ T cells in the blast 
population. The amount of granzyme A is normally higher 
than that of granzyme B in cytotoxic T lymphocytes, and 
its detection in exosomes is in agreement with the previous 
observation on the presence of granzymes not only in 
simple cytoplasmic granules, but also in MVB inside CTL, 
being secreted afterwards associated with exosomes which 
also express the TCR/CD3 complex [7]. Indeed, we have 
detected CD3 components in exosomes from both T cell 
blasts and Jurkat cells, also in agreement with a previous 
immunoblot study on exosomes from human T cells [51].
The proteins identified in our study are mainly 
coincident with the most thorough study on T cell exosomes 
published to date, although in that case corresponded to 
exosomes from murine T cells [60]. Major proteins included 
actin, tubulin, cytoskeleton and microtubule related 
proteins, and also ribosomal and mRNA granule proteins. 
Especially interesting is the presence of the tetraspanin 
CD81, expressed in exosomes from both Jurkat cells and T 
cell blasts, and that has been recently described to direct the 
sorting of proteins towards exosomes [60].
The fact that the major proteins in exosome 
composition are cytoskeletal, ribosome and mRNA granule 
proteins reflects the mechanism of exosome generation, 
by inward vesiculation of the limiting multivesicular 
membrane. This makes that the major exosome proteins 
are indeed the major cytoplasmic proteins, including 
cytoskeletal proteins, ribosomal and mRNA granule 
proteins in cells that are activated and dividing. Hence, 
we propose that membrane proteins have a higher chance 
to perform specific functions. This is not an affirmation 
that holds true for all the soluble proteins inside exosomes, 
for example, one of the major proteins identified in 
exosomes from both Jurkat and T cell blasts, HNRPA2B1, 
has been recently shown to increase the expression of 
specific miRNAs in exosomes [52]. Good examples of 
membrane proteins expressed on the surface of exosomes 
and involved in functional responses are FasL, Apo2L/
TRAIL, and also CD81, as commented above. However, 
these proteins are expressed in exosomes from both Jurkat 
and human T cell blasts, and the main goal of our study 
was to identify proteins that were exclusively expressed 
on exosomes from one type or cell or the other. We found 
that 24 membrane proteins are especially enriched in 
exosomes from T cell blasts, and that the reverse situation 
occurred for 14 proteins enriched in Jurkat cell exosomes. 
Proteins expressed in exosomes from normal human T 
cell blasts included HLA proteins and β2-microglobulin, 
and many CD proteins, such as CD2, CD5, CD46, CD48, 
CD58, CD44, CD38, CD6, CD97, Fas/CD95, LFA-1 
and β2-integrin. All these proteins are related with the 
physiological function of these immune cells, and are lost 
in the exosomes of leukemic cells. This result suggests 
that one differential paradigm of exosomes from tumoral 
cells is the loss of membrane proteins involved in normal 
cell function.
Regarding membrane proteins that are enriched 
in exosomes from Jurkat cells, most of them are related 
with vesicular traffic, indicating that these processes, 
including exosome generation and secretion, seem to be 
more active in tumoral cells. This is demonstrated also by 
the higher secretion rate of exosomes in tumoral cells at 
the basal level. The most abundant of these proteins was 
VCP and, as a first possible application of this study, we 
have validated the different expression of this protein in 
both types of exosomes. p97/VCP is a membrane ATPase 
involved in ER homeostasis and ubiquitination [53], 
that is associated with tumoral transformation, having 
prognostic value, at least in gastric carcinoma [54]. It has 
been shown recently that VCP inhibition by the specific 
inhibitor DBeQ [61] or also by sorafenib [62] could have 
therapeutic interest in cancer treatment. We show that 
Jurkat tumoral cells, and also other leukemic human cells, 
such as U937 and Mec1, are more sensitive to cell death 
induced by the VCP inhibitor DBeQ than normal human 
T cells, suggesting a new selective pathway to exploit in 
cancer treatment. In addition, we show that VCP inhibition 
preventsfunctionalexosome secretion only in Jurkat 
cells, but not in T cell blasts. This suggests that VCP is 
implicated in the process of exosome generation and/or 
secretion, but this implication is important only in tumoral 
Jurkat cells, but not in normal human T cell blasts.
Oncotarget14www.impactjournals.com/oncotarget
Exosome secretion is common in tumoral cells, 
and it has a pro-tumorigenic function, at least through 
suppression of anti-tumoral immune surveillance [41]. 
However, many other unknown mechanisms that promote 
tumorigenesis could be associated with exosome secretion 
by tumor cells, such as the transfer of specific miRNAs 
[50]. Recent studies indicate the specific association of 
some proteins such as MET in the case of melanoma, and 
glypican-1 in the case of pancreatic cancer with exosomes, 
and their role in promoting the malignant transformation 
[63, 64]. We have not detected these proteins in our 
exosomes, since their distribution could be tissue-
specific, but the targeting of VCP could decrease exosome 
generation in several tumor models, offering an interesting 
new avenue for cancer treatment.
The approach to study membrane proteins has been 
a first step and other membrane or soluble proteins can be 
studied in future work. For example, YBX-1 and p85Mcm/
MCM7 are also major proteins in the exosomes of Jurkat 
cells, but are absent from the exosomes of T cell blasts. 
YBX-1 is a translation repressor of specific mRNAs, 
is over-expressed in some tumors, and it increases the 
expression of the multidrug resistance receptor (MDR) 
in especially aggressive tumors [65]. On the other hand, 
p85Mcm/MCM7 is a nuclear protein belonging to the 
minichromosome maintenance family, which oncogenic 
activity has been recently recognized [66].
MATERIALS AND METHODS
Cells and cell culture
The Jurkat T-cell leukemia (ATCC, clone E6.1), 
U937 histiocytic lymphoma, and the Mec1 chronic 
lymphocytic leukemia cell line were cultured in RPMI 
1640 medium (Gibco, Barcelona, Spain) supplemented 
with 10% fetal calf serum, Image-glutamine and penicillin/
streptomycin (hereafter, complete medium) using standard 
cell culture procedures.
Human peripheral blood mononuclear cells (PBMC) 
were obtained from blood of healthy donors by Ficoll-
Paque density centrifugation, as indicated elsewhere [67]. 
T-cell blasts were generated as follows: PBMC (2x106 
cells/ml) were stimulated during 1 day with 5 μg/ml 
phytohemagglutinin (PHA). Afterwards, PHA was washed 
out, cells suspended in complete medium supplemented 
with 30 UI/ml interleukin-2 and cultured for 5 days with 
medium changes every 48 h.
Exosome purification
After washing twice in RPMI-1640 medium without 
serum, 250 x 106 Jurkat cells or 500 x 106 of T-cells blasts 
were suspended in 15 ml of this same medium and re-
stimulated by incubation with 50 μg/ml PHA at 37 °C for 
5 min. Cells were washed three times with RPMI-1640, 
suspended in 15 ml RPMI-1640 and incubated for 1 hour 
at 37 °C. Supernatants were collected by centrifugation 
for 5 min at 300 x g. Supernatants were clarified by two 
sequential centrifugations, the first at 1,800 x g for 20 min 
and the second at 10,000 x g for 30 min. Exosomes were 
finally isolated by ultracentrifugation at 110,000 x g for 8 
hours with a SW40 Ti rotor (Beckmann).
Immunoelectron transmission microscopy of 
exosomes
Exosomes were isolated from supernatants of T cell 
blasts after treatment with PHA as indicated above, or with 
immobilized anti-CD59 mAb for 3h. Immunogold labeling 
of exosomes was performed essentially as described in [40]. 
Briefly, formvar-coated copper grids, wet with bacitracin 
at 7.5 μg/ml for 2 minutes, were placed on 15 μl aliquots 
of the exosome preparation for 10 minutes, and then fixed 
with 3% paraformaldehyde for 5 minutes. Double FasL 
and Apo2L/TRAIL labeling was performed by using the 
N20 rabbit pAb (lot D159) at 6 μg/ml and the anti-Apo2L/
TRAIL mouse mAb 5C2 at 25 μg/ml plus anti-rabbit IgG 
and anti-mouse IgG coupled to colloidal gold particles 15 
nm and 5 nm in size, respectively, at 1/50 dilution. Finally, 
grids were negatively stained with uranyl acetate for 1 
minute, and examined in a Jeol JEM 1010 transmission 
electronic microscope (Jeol, Barcelona, Spain) at 80 kV. 
In the conditions described, the labeling was exclusively 
associated with exosomes, with no labeling outside 
membranous structures. In these conditions, no labeling 
was observed when using the secondary antibodies alone or 
irrelevant rabbit or mouse IgG.
Lipid analysis
For analysis and quantification of the lipid 
composition of cells and exosomes secreted from the 
cells, we first performed [14C]-acetate metabolic labeling 
of the cells during 72h. After that, cells were stimulated 
as indicated above for exosome secretion, cells separated 
from supernatants by centrifugation, and exosomes 
isolated as indicated above. After that, cell or exosome 
lipids were extracted with chloroform/methanol (2:1, v/v) 
and lipids separated by thin-layer chromatography (TLC). 
Phospholipid separation was made using chloroform/
methanol/32% ammonia (65:35:5, v/v; [68]) as eluent. 
Neutral lipid separation was made using the standard 
eluent hexane/ethyl ether/acetic acid (70:30:1, v/v; 
[69]). Radiolabelled lipids in TLC plates were located 
by autoradiography (Hyperfilm β-max, Amersham) at 
room temperature for 2 days and radioactivity quantified 
by liquid scintillation counting of scrapped silicagel. In 
all TLC analysis, positions of the authentic lipids were 
identified by running commercial standards of all lipid and 
phospholipid classes (Sigma, Madrid, Spain) in the same 
plates, and revealing them with iodine.
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2-D electrophoresis
5x106 cells were washed with PBS and solubilized in 
100 μl lysis buffer (6M Urea, 2M Thiourea, 1% Triton, 40 
mM Tris, 60 mM DTT and Complete Mini (EDTA free)) 
by incubating on ice during 30 minutes and centrifugation 
15 minutes at 13,500 rpm. Supernatant was collected and 
protein concentration was quantified with Coomasie® 
Plus Protein Assay Reagent following the manufacturer’s 
protocol. Exosomes from 250 x 106 Jurkat or 500 x 106 
T-cells blasts were lysed in 500 μl of the same lysis buffer 
and protein concentration was quantified with Coomasie® 
Plus Protein Assay Reagent following the manufacturer’s 
protocol.
Analytical loadings of 30 μg of protein were 
suspended in rehydration buffer (6M Urea, 2M Thiourea, 
2% CHAPS, 18 mM DTT, 0,8% IPG Buffer, Bromophenol 
Blue) to a final volume of 350 μl. Samples were applied 
to IPG strips 18 cm pH 3-10 by in-gel rehydration, over-
night at room temperature. Four-step-focusing (step 1, 1h, 
500 V, step and hold; step 2, 1000V, step and hold; step 
3, 1h, 8000V, linear gradient; step 4, 8h, 8000V, step and 
hold) was performed with an IPGphor system (Amersham 
Biosciences, Freiburg, Germany) for 65 kVh. Strips were 
equilibrated for 60 min in 50 mM Tris-HCl pH 8,8 buffer 
containing 6 M urea, 30% glycerol, 2% SDS, 1% DTT 
and 0,01% bromophenol blue, then treated for 60 min in 
the same buffer containing 2,5% iodoacetamide instead of 
DTT. The strips were then transferred onto 10% SDS-PAGE 
gels (200 x 250 x 1.00 mm) for the 2-D separation (DALT 
system, 90 V constant voltage, overnight run at 20 °C).
Silver staining was performed as described before [70]. 
Silver stained gels were scanned using a LabScan Imager 
Scanner (Amersham Biosciences, Freiburg, Germany). 
The resulting 2-D protein patterns were analyzed, using 
the programs LabScan 3.00 and Image Master 2-D Elite 
(Amersham Biosciences, Freiburg, Germany).
Immunoblot analysis
Extracts with urea were dialyzed in two steps. In the 
first step, extracts were dialyzed against 4M urea, 137 mM 
sodium chloride, 20 mM tris, 1 mM EDTA and 1% Triton 
X-100 during 4 hours at 4 °C. In the second step, extract 
were dialyzed against 137 mM sodium chloride, 20 mM 
tris, 1 mM EDTA and 1% Triton X-100 over night at 4 °C. 
5 μg of protein were analyzed by NuPAGETM 12% Bis-
Tris Gels (Invitrogen) and separated proteins transferred 
to PVDF membranes (Millipore).
To analyze supernatants before and after 
ultracentrifugation, supernatants were treated with 10% 
trichloroacetic acid (Roth, Germany) during 15 min on ice. 
Supernatant were centrifuged during 15 min to 13000g 
at 4 °C, washed with ice-cold acetone and centrifuged 
during 5 min to 13000g at 4 °C. Precipitates were solved 
in PBS with 1% SDS, 1% triton X-100 and Complete Mini 
(EDTA free) during 30 min on ice. Protein concentration 
was quantified with Coomasie® Plus Protein Assay 
Reagent following the manufacturer’s protocol. 10 μg of 
protein were analyzed by NuPAGETM 10% Bis-Tris Gels 
(Invitrogen) and separated proteins transferred to PVDF 
membranes (Millipore).
The antibodies used were mouse mAb against 
human Grp94, Hsp90, Hsc70/Hsp70, Hsp60, Hsp40 
and TCP-1α (SPA-850, SPA-830, SPA-820, SPA-806, 
SPA-450 and CTA-122, Stressgen Biotechnologies, 
Victoria, Canada), Rab5 and Lck (BD Biosciences), 
β-actin, α-tubulin (clone AC-15 and clone B-5-1-2, 
Sigma), and α-actin (Santa Cruz, sc-1615). CD63 was 
detected using the mAb TEA3/18, a kind gift from Dr. 
Noa Martín-Cófreces, from Fundación CNIC, Madrid. 
Apo2L/TRAIL was revealed using the rabbit polyclonal 
antibody C35, kind gift from Avi Ashkenazi, Genentech, 
South San Francisco, USA. FasL was detected in cell 
and exosome extracts using a rabbit polyclonal antibody 
produced previously in our laboratory using cDNA 
immunization [71]. VCP was detected in cell and exosome 
extracts using a rabbit polyclonal antibody from Cell 
Signalling (Barcelona, Spain), especially optimized for 
immunoblot. Immunoblots were revealed by enhanced 
chemiluminiscence (Pierce, USA).
Protein identification by mass spectrometry
MALDI-TOF
30 μg protein were runned in the same conditions 
as for silver staining. Gels were fixed with 50% methanol 
and 2% o-phosphoric acid over night. After that, gels 
were washed three times with distilled water during 20 
min and incubated with 34% methanol, 2% o-phosphoric 
acid and 17% ammonium sulfate during 1 hour. Gels were 
stained with 34% methanol, 2% o-phosphoric acid, 17% 
ammonium sulfate and 0,066% Coomasie G-250 during 
at least 5 days. Finally, gels were distained with 25% 
methanol during 1 min and kept in distilled water until 
excising. Identified spots were excised from the gel and 
spotted on a MALDI AnchorChip target plate according to 
the manufacturer’s instructions. Analysis was performed 
on an OrbitrapXL MALDI TOF instrument (Thermofisher) 
using Bruker Flex-control, Flex-analysis, and Biotools 
software. Calibration was performed externally using 
SIGMA Proteo- Mass™ Peptide MALDI–MS Calibration 
Kit. MALDI mass spectra were recorded within an m/z 
range of 700–3500 in the positive ion reflector mode. Mass 
spectra were obtained by averaging up to 300 individual 
laser shots. Each analysis was performed in triplicate.
LCMSMS
Protein samples were digested overnight at 37 °C 
with 60 ng/μl trypsin in 50 mM ammonium bicarbonate, 
pH 8.8, containing 10% acetonitrile and 0.01% 
5-cyclohexyl-1-pentyl-β-D maltoside. Tryptic peptide 
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mixtures were separated using a nanoAcquity UPLC 
system (Waters GmbH, Eschborn, Germany). The nano 
UPLC system was coupled online to an LTQ Orbitrap 
XL mass spectrometer (Thermo Scientific, Bremen, 
Germany). Data were acquired by scan cycles of one 
FTMS scan with a resolution of 60000 at 400 m/z and a 
range from 370 to 2000 m/z in parallel with six MS/MS 
scans in the ion trap of the most abundant precursor ions. 
The mgf-files were used for database searches with the 
MASCOT search engine (Matrix Science, London, UK). 
Using this software, P< 0.05 was used as the detection 
criteria taken for the protein identification, meaning that 
all proteins identified has a probability of less than 5% to 
be false positives.
Bioinformatics treatment of data
Using the uniprot ID numbers obtained, the protein 
name, species and function, together with their inclusion 
in different metabolic pathways was analyzed using 
the David software (http://david.abcc.ncifcrf.gov/list.
jsp). Interaction profiles between the different proteins 
identified were represented using the STRING software 
(http://string-db.org/), and the significance for clustering 
in a given group was also calculated, being P≤ 0.012 for 
all the interaction nodes identified.
Functional assays performed with the DBeQ 
VCP inhibitor
To estimate the functional value of VCP expression 
in the exosomes of tumoral Jurkat cells but not in those 
from normal T cell blasts, we performed several functional 
assays using the VCP inhibitor N2,N4-dibenzylquinazoline-
2,4-diamine, also termed DBeQ [61].
Dose-response effect of DBeQ on cell growth and cell 
viability
Jurkat cells or human 6-day T-cell blasts were 
incubated overnight with increasing doses of DBeQ, 
from 3 to 6 μM, and cellular growth in comparison with 
non-treated control cells estimated by the MTT method, 
and cell death determined by Trypan blue staining and 
counting in an hemocytometer. Previously to establish this 
range of concentrations, which are not extremely toxic, 
DBeQ concentrations from 1 to 30 μM were tested.
Effect of DBeQ on cytotoxic exosome secretion from 
Jurkat or T cell blasts
To estimate the effect of DBeQ on this functional 
response, we used a bioassay previously optimized 
by our group [55, 56]. As controls, we performed also 
assays using the agonistic anti-Fas mAb CH11 (Upstate, 
Lake Placid, USA) at 50 ng/ml or recombinant TRAIL 
produced in our laboratory (e.g., see ref. 31) at 1 μg/ml, in 
the presence or absence of 3 μM DBeQ and/or the general 
caspase inhibitor Z-VAD-fmk (Bachem, Bubendorf, 
Switzerland) at 30 μM. For supernatant testing, Jurkat 
cells or T cell blasts were preincubated or not during 16h 
with 3 μM DBeQ, and, after washing out the inhibitor, 
cells were stimulated with 10 ng/ml of phorbol myristate-
acetate (PMA) plus 600 nM ionomycin during 2h. Cell 
supernatants of stimulated cells were recovered by 
centrifugation, and tested overnight against non-activated 
Jurkat cells, as indicated in [56]. Cell death was estimated 
in these experiments by nuclear staining of dead cells with 
7-amino-actinomycin D (7-AAD) and flow cytometry. In 
our previous studies we have shown that cytotoxicity on 
Jurkat cells of these supernatants is mainly due to FasL 
and Apo2L/TRAIL secretion associated with exosomes [8, 
56, 57], being thus a functional test of exosome secretion.
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